PMID- 17644313
OWN - NLM
STAT- MEDLINE
DCOM- 20071024
LR  - 20160526
IS  - 0920-9964 (Print)
IS  - 0920-9964 (Linking)
VI  - 95
IP  - 1-3
DP  - 2007 Sep
TI  - Symptomatic remission in schizophrenia patients treated with aripiprazole or 
      haloperidol for up to 52 weeks.
PG  - 143-50
AB  - BACKGROUND: The Remission in Schizophrenia Working Group (RSWG) has defined 
      criteria for symptomatic remission based on achieving and maintaining a 
      consistently low symptom threshold for at least six consecutive months. This 
      analysis examined symptomatic remission in acutely ill patients with 
      schizophrenia receiving either aripiprazole or haloperidol for one year. METHODS: 
      Pooled data from two 52-week, randomized, double-blind, multicenter, comparative 
      trials of aripiprazole and haloperidol in acutely ill patients with schizophrenia 
      were analyzed. Measures of symptomatic remission were calculated according to 
      RSWG criteria. RESULTS: Remission rates were significantly higher for patients 
      treated with aripiprazole compared with haloperidol (32% vs 22%, respectively; 
      p<0.001, LOCF). Among remitters, aripiprazole-treated patients achieved symptom 
      criteria in a significantly shorter time than haloperidol-treated patients (log 
      rank p=0.0024). For trial completers, remission rates were similarly high in both 
      groups (aripiprazole, 77%; haloperidol, 74%). Regardless of treatment type, 
      remitters received significantly higher global clinical ratings than nonremitters 
      (p<0.0001). Aripiprazole was associated with a significantly lower rate of 
      discontinuations due to adverse events (AEs) than haloperidol (8.0% vs 18.4%, 
      respectively; p<0.001) as well as lower concomitant medication use for 
      extrapyramidal symptoms (EPS) (23% vs 57%, respectively; p<0.001). CONCLUSION: 
      Acutely ill schizophrenia patients treated with aripiprazole demonstrated a 
      significantly higher rate of symptomatic remission across 52 weeks compared with 
      haloperidol-treated patients. The similar remission rates among trial completers 
      in both treatment groups, combined with fewer AE-related discontinuations and 
      lower EPS medication use in the aripiprazole group, suggest that better 
      tolerability with aripiprazole may have contributed to superior overall remission 
      rates.
FAU - Kane, John M
AU  - Kane JM
AD  - The Zucker Hillside Hospital, 75-59 263 St., Glen Oaks, NY 11004, USA. 
      sschiavi@lij.edu
FAU - Crandall, David T
AU  - Crandall DT
FAU - Marcus, Ronald N
AU  - Marcus RN
FAU - Eudicone, James
AU  - Eudicone J
FAU - Pikalov, Andrei 3rd
AU  - Pikalov A 3rd
FAU - Carson, William H
AU  - Carson WH
FAU - Swyzen, Wim
AU  - Swyzen W
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20070717
PL  - Netherlands
TA  - Schizophr Res
JT  - Schizophrenia research
JID - 8804207
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Piperazines)
RN  - 0 (Quinolones)
RN  - 82VFR53I78 (Aripiprazole)
RN  - J6292F8L3D (Haloperidol)
SB  - IM
MH  - Acute Disease
MH  - Antipsychotic Agents/adverse effects/*therapeutic use
MH  - Aripiprazole
MH  - Basal Ganglia Diseases/chemically induced
MH  - Double-Blind Method
MH  - Haloperidol/adverse effects/*therapeutic use
MH  - Humans
MH  - Longitudinal Studies
MH  - Piperazines/adverse effects/*therapeutic use
MH  - Prospective Studies
MH  - Psychiatric Status Rating Scales/statistics & numerical data
MH  - Quinolones/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Research Design/standards
MH  - Schizophrenia/diagnosis/*drug therapy
MH  - *Schizophrenic Psychology
MH  - Survival Analysis
MH  - Treatment Outcome
EDAT- 2007/07/24 09:00
MHDA- 2007/10/25 09:00
CRDT- 2007/07/24 09:00
PHST- 2007/01/31 00:00 [received]
PHST- 2007/04/30 00:00 [revised]
PHST- 2007/05/01 00:00 [accepted]
PHST- 2007/07/24 09:00 [pubmed]
PHST- 2007/10/25 09:00 [medline]
PHST- 2007/07/24 09:00 [entrez]
AID - S0920-9964(07)00200-9 [pii]
AID - 10.1016/j.schres.2007.05.009 [doi]
PST - ppublish
SO  - Schizophr Res. 2007 Sep;95(1-3):143-50. doi: 10.1016/j.schres.2007.05.009. Epub 
      2007 Jul 17.